Ziccum AB (publ) releases Annual Report 2023

  • by Mark Du Bois

    • Ziccum today announces that its Annual Report for 2023 is now available on the company’s website www.ziccum.com.

    To read the Report in full (in Swedish) please visit here: https://ziccum.com/investors/financial-reports/

    For more information about Ziccum, please contact:

    Ann Gidner,
    CEO Ziccum
    Mail: gidner@ziccum.com
    Mobile: +46 722140141

    Fredrik Sjövall,
    Chairman of the Board, Ziccum AB
    Mail: sjovall@ziccum.com
    Mobile: +46 706 45 08 75
     
    Ziccum’s Certified Adviser is
    Carnegie Investment Bank AB (publ).
    Follow us on https://eucaps.com/ziccum

    About Ziccum

    Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

    Attachments

    Ziccum AR 2023

    Ziccum AR 2023